U.S. regulators have approved the first-ever therapy specifically for acquired hypothalamic obesity (aHO), a rare and severe form of weight gain that can follow brain injury, after results from the largest clinical trial ever conducted for the condition were published.
The treatment is setmelanotide, a melanocortin-4 receptor (MC4R) agonist. Lurie Children’s Hospital of Chicago and Northwestern University announced on 15 July 2026 that the Phase 3 TRANSCEND trial — the longest and largest study in people with aHO — showed robust improvements in both weight and hunger among adults and children aged four years and older. The findings were simultaneously reported through NEJM-associated research channels.
What is acquired hypothalamic obesity?
Acquired hypothalamic obesity is caused by damage to the hypothalamus, a small region of the brain that regulates hunger, fullness and how the body uses energy. Because those signals stop working properly, patients experience constant hunger, a slowed metabolism and rapid weight gain that is resistant to diet and exercise alone. It most often develops after surgery or radiation for certain childhood brain tumours, but can also follow traumatic brain injury or stroke.
Why the approval is significant
Until now there was no FDA-approved treatment aimed at the underlying biology of the disorder — only off-label approaches. Setmelanotide works on the same MC4R pathway already used in rare genetic forms of obesity, but the new approval extends it to the acquired form, moving care from “investigational hope” to standard of care for a clearly defined group of patients.
Clinicians caution that the therapy is targeted, not a general weight-loss drug, and is intended for people with hypothalamic injury rather than the broader population. As with any new medication, treatment decisions should be made with a specialist familiar with the condition.